Emerging Therapeutic Agents for Colorectal Cancer

Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri

doi:10.3390/molecules26247463

Molecules (Dec 2021)

Emerging Therapeutic Agents for Colorectal Cancer

Marianna Nalli,
Michela Puxeddu,
Giuseppe La Regina,
Stefano Gianni,
Romano Silvestri

Affiliations

Marianna Nalli: Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy
Michela Puxeddu: Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy
Giuseppe La Regina: Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy
Stefano Gianni: Department of Biochemical Sciences “Rossi Fanelli”, Institute of Biology and Molecular Pathology of CNR, Sapienza University of Rome, 00185 Rome, Italy
Romano Silvestri: Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy

DOI: https://doi.org/10.3390/molecules26247463
Journal volume & issue: Vol. 26, no. 24
p. 7463

Abstract

Read online

There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.

Published in Molecules

ISSN: 1420-3049 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Chemistry: Organic chemistry
Website: http://www.mdpi.com/journal/molecules

About the journal

Abstract

Keywords